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Peroxisomeproliferator-activatedreceptord (PPARd)
is a critical regulator of energy metabolism in the
heart. Here, we propose a mechanism that inte-
grates two deleterious characteristics of heart fail-
ure, hypoxia and a metabolic shift toward glycolysis,
involving the microRNA cluster miR-199a214 and
PPARd. We demonstrate that under hemodynamic
stress, cardiac hypoxia activates DNM3os, a
noncoding transcript that harbors the microRNA
cluster miR-199a214, which shares PPARd as
common target. To address the significance of
miR-199a214 induction and concomitant PPARd
repression,weperformedantagomir-based silencing
of both microRNAs and subjected mice to biome-
chanical stress to induce heart failure. Remarkably,
antagomir-treated animals displayed improved car-
diac function and restored mitochondrial fatty acid
oxidation. Taken together, our data suggest a mech-
anism whereby miR-199a214 actively represses
cardiac PPARd expression, facilitating a metabolic
shift from predominant reliance on fatty acid utiliza-
tion in the healthy myocardium toward increased
reliance on glucose metabolism at the onset of heart
failure.Cell MeINTRODUCTION
Despite the remarkable metabolic flexibility of the heart
regarding nutritional status and cardiac demand, several studies
demonstrated abnormalities in cardiac lipid homeostasis and
energy production as a consistent feature of heart failure (HF)
(Barger and Kelly, 2000; Razeghi et al., 2001). Due to limited
oxygen and fatty acid availability, the fetal heart mainly relies
on anaerobic glucose utilization. In contrast, rising cardiac
work and the abundance of fatty acids in the postnatal heart
bring about increased reliance onmitochondrial fatty acid oxida-
tion (FAO). Hemodynamically stressed hearts exhibit a return to
the fetal metabolic pattern that is hallmarked by impaired mito-
chondrial FAO and a shift to further reliance on glucose meta-
bolism (Rajabi et al., 2007; Razeghi et al., 2001). Due to the strict
aerobic nature of the heart and the inability to generate sufficient
energy under anaerobic conditions, reliance on glycolysis has a
major impact on available ATP levels (Di Lisa et al., 2007). As
such, hypoxia is considered to be a characteristic of the failing
heart (Giordano, 2005; Sabbah et al., 2000; Tanaka et al., 1994).
Regulation of the metabolic profile by activity of the peroxi-
some proliferator-activated receptor d (PPARd) has been shown
to play a role in themetabolic switch from FAO to glycolysis (Bur-
kart et al., 2007). Heart muscle-restricted deletion of PPARd re-
sulted in progressive lipid accumulation, cardiac hypertrophy,
and congestive heart failure (Cheng et al., 2004). Conversely, se-
lective overexpression of PPARd in themouse heart provoked an
increase in myocardial glucose utilization with no myocardialtabolism 18, 341–354, September 3, 2013 ª2013 Elsevier Inc. 341
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MicroRNA Regulation of Cardiac Energy Metabolismlipid accumulation due to preserved FAO and resistance to car-
diac disease induced by ischemia reperfusion injury (Burkart
et al., 2007). These studies clearly illustrate the importance of
PPARd signaling in energy homeostasis and pathogenesis of
heart failure. Despite this, whether and how PPARd is regulated
remains unclear.
Small noncoding RNAs (18–24 nucleotides), such as micro-
RNAs (miRNAs, miRs), have been shown to be a fascinating
mechanism, coordinating complex programs of gene expression
(da Costa Martins et al., 2008; Thum et al., 2007; van Rooij et al.,
2007). By regulating the stability and translation of messenger
RNAs by base-pairing with the 30 UTRs, miRNAs have been
shown to impact gene expression in cardiovascular disease
(da Costa Martins et al., 2008; Thum et al., 2007). In a compara-
tive study among animal models of pathological cardiac remod-
eling, miR-199a and miR-214 showed increased expression in
these animal models as well as in samples of failing human
hearts (van Rooij et al., 2006). In addition, expression of these
miRNAs induced a hypertrophic response in cardiomyocytes,
suggesting that miR-199a and miR-214 are involved in the pro-
cesses leading to cardiac disease (van Rooij et al., 2006).
Despite their apparent role in cardiac remodeling, the mecha-
nisms driving the regulation of miR-199a and miR-214 in the
failing heart and how these miRNAs provoke deleterious cardiac
remodeling remain undefined.
We report here that the miRNA cluster miR-199a214,
embedded in chromosome 1 in a large noncoding RNA,
Dnm3os, actively represses PPARd. Furthermore, myocardial
hypoxia provokes Dnm3os activation and concomitant
miR-199a214 expression. Increased expression of miR-199a
and miR-214 promotes decreased cardiac PPARd expression,
mitochondrial disarray and I band widening, and decreased
mitochondrial fatty acid oxidative capacity. Conversely, antago-
mir-based silencing ofmiR-199a214 in mice subjected to pres-
sure overload derepressed cardiac PPARd levels, normalized
mitochondrial fatty acid oxidation, and improved cardiac struc-
ture and function. Taken together, our data suggest a mecha-
nism whereby myocardial hypoxia, a hallmark of heart failure,
induces expression of members of the miRNA cluster
miR-199a214, which actively downregulate cardiac PPARdFigure 1. Expression of the miR-199a214 Cluster Targets PPARd
(A) Schematic representation of genomic localization and precursor of hsa-miR-1
on the opposite strand in intron 14 of the dynamin-3 (DNM3) gene, on chromos
phylogenetically conserved.
(B) Northern blot analysis of miR-199a and miR-214 expression in hearts from s
2008). Rnu6-2 was used as a loading control.
(C) Quantification of Rnu6-2-corrected northern blot signals for miR-199a and m
(D and E) Real-time PCR analysis of transcript abundance formiR-199a,miR-214
nonfailing and dilated cardiomyopathy (DCM) patient-derived left ventricular myo
(F) Location of miR-199a and miR-214 seed regions in human and mouse PPAR
(G) Western blot analysis of endogenous PPARd and GAPDH in nonfailing and d
(H) Quantification of GAPDH-corrected protein levels of PPARd from (G).
(I) Schematic representation of luciferase reporter constructs harboring intact or
(J) Activity assay of luciferase reporter constructs harboring intact PPARd 30 UTR
synthetic precursor for miR-199a and/or with miR-214. A scrambled miRNA prec
(K) Western blot analysis of endogenous PPARd and GAPDH in neonatal rat ca
miR-214. Transfection with scrambled synthetic precursor was used as a negati
(L) Western blot analysis of endogenous PPARd and GAPDH in neonatal rat cardio
adenovirus lacking the 30 UTR of PPARd (Ad-PPARd-D30 UTR), with or without tra
corresponding control group; #p < 0.05 versus corresponding experimental grou
Cell Meexpression, provoking a switch toward amitochondrial glycolytic
metabolic profile that contributes to characteristics of heart
failure.
RESULTS
The miR-199a:214 Cluster Is Increased in Human and
Mouse Heart Failure
Recent cardiac microRNA profiling studies from our group and
others have shown that the expression of both miR-199a and
miR-214 is increased in various models of heart failure (da Costa
Martins et al., 2010; Leptidis et al., 2013; van Rooij et al., 2006).
Human miR-199a214 is encoded by a large noncoding RNA,
DNM3os, which is transcribed in the opposite strand of the
DNM3 gene (Figure 1A). Both mature miRNAs, hsa-miR-199a-
2-5p and hsa-miR-214-3p, are evolutionary conserved among
several species (Figure 1A). Northern blot analysis confirmed
that both miR-199a and miR-214 are upregulated in hearts
from mice subjected to pressure overload by transverse aortic
constriction (TAC) (Figures 1B and 1C). Quantitative RT-PCR
also showed an increase in DNM3os expression in TAC-oper-
ated mice, verifying the clustered expression of both miRs
in failing mouse hearts (Figure 1D). An increased expression
of DNM3os, along with the encoded miRNA cluster
miR-199a214, was also evident in biopsies of cardiac tissue
from heart failure patients (Figure 1E).
Mechanistically, miR-199a and miR-214 are predicted to
targetmultiple genes according to several public data sets. Inter-
estingly, we identified PPARd as a predicted common target of
both microRNAs. Indeed, investigation of the 30 UTR of PPARd
revealed an evolutionarily conserved seed region for miR-214
in both human andmouse PPARd and a less-conserved seed re-
gion for miR-199a (Figure 1F). Next, we examined whether
PPARd levels are affected in biopsies of cardiac tissue from heart
failure patients. Western blot analysis in biopsies of cardiac tis-
sue from heart failure patients showed lower protein levels of
PPARd compared with human control heart tissue (Figures 1G
and 1H).
To further confirm the functionality of the seed regions ofmiR-
199a andmiR-214, we fused the 30 UTR of PPARd to a luciferase99a and hsa-miR-214, encoded by the large noncoding RNA DNM3os, located
ome 1 in the human genome. The mature miR-199a and miR-214 strands are
ham mice or mice subjected to transverse aortic constriction (Bourajjaj et al.,
iR-214 from (B).
, and DNM3os in hearts from sham mice and mice subjected to TAC (D) and in
cardium (E).
d 30 UTR.
ilated cardiomyopathy patient-derived left ventricular myocardium.
mutated PPARd 30 UTR.
or mutated seed regions for eithermiR-199a ormiR-214, after transfection with
ursor was used as a control.
rdiomyocytes transfected with synthetic precursor for miR-199a and/or with
ve control.
myocytes infected with control adenovirus harboring the lacZ gene (Ad-lacZ) or
nsfection of synthetic precursors formiR-199a and miR-214. *p < 0.05 versus
p (error bars are SEM). See also Figure S1.
tabolism 18, 341–354, September 3, 2013 ª2013 Elsevier Inc. 343
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(Figure 1I). Coexpression of syntheticmiR-199a and/ormiR-214
decreased PPARd 30 UTR reporter activity (Figure 1J), while
mutating the seed regions for miR-214 in the PPARd 30 UTR re-
porter construct abrogated the inhibitory effect of miR-214 and
miR-199a. Mutating the seed region for miR-199a only had an
inhibitory effect onmiR-199a transfection (Figure 1J; Figure S1A
available online), indicating a dominant effect of miR-214 on
PPARd repression and establishing the causative link between
posttranslational control by the miRNA cluster miR-199a214
on PPARd. To further verify whether increased miR-199a214
levels are directly responsible for the decrease of PPARd protein
levels in the failing hearts, we overexpressed synthetic precur-
sors formiR-199a and/ormiR-214 in a dose-dependent manner
and observed efficient downregulation of endogenous PPARd
expression (Figure 1K). Finally, we overexpressed a form of
PPARd lacking a 30 UTR and demonstrated that this form of
PPARd was insensitive to precursor transfection of miR-199a
and miR-214 (Figures 1L and 1M). Taken together, these data
demonstrate that miR-199a and miR-214, as well as their host
gene Dnm3os, are increased in human and mouse heart failure
and directly target PPARd.
Hypoxia Drives the Expression ofmiR-199a214
through Hif1a/Twist1
Myocardial hypoxia has been associated with a variety of clinical
conditions, including ischemic heart disease (IHD), systemic hy-
pertension, and pathological cardiac hypertrophy, where the
hypoxia-inducible transcription factor 1a (Hif1a) drives hypox-
ia-inducible gene expression (Lei et al., 2008; Rey and Semenza,
2010). One Hif1a downstream mechanism employs the activa-
tion of the transcription factor Twist1 by binding directly to the
hypoxia response element (HRE) in the Twist1 proximal pro-
moter (Yang et al., 2008). Interestingly, DNM3os has been iden-
tified as a target gene for the helix-loop-helix transcription factor
Twist1 (Loebel et al., 2005). To verify the functionality of this
element, a luciferase reporter harboring the proximal DNM3os
promoter region was generated and tested for Hif1a or Twist1
sensitivity (Figure 2A). The DNM3os-luc reporter demonstrated
activation upon cotransfection with Hif1a or Twist1, while the
enhancer box (E box)-mutated DNM3os-luc reporter construct
showed no activation under the same conditions (Figure 2B).
Dnm3os homozygous-deficient mice die within 1 month of
birth accompanied by skeletal abnormalities, defects in dorsal
neural arches and spinous processes of the vertebrae, osteope-
nia, and reduced expression of its host genes miR-199a and
miR-214 (Watanabe et al., 2008). We reasoned that Dnm3os-
deficient hearts may display derepression of PPARd due to the
reduced expression of miR-199a214. In line, western blotting
demonstrated increased PPARd expression in Dnm3os-defi-
cient hearts compared to hearts from wild-type (WT) littermates
(Figures 2C and 2D). The premature death of juvenile Dnm3os-
deficient mice precluded further functional studies.
The PPARd 30 UTR reporter also showed strong inhibition of
luciferase activity under hypoxia, with peak activity on day 3 (Fig-
ure 2E), confirming both the hypoxia-sensitive and microRNA-
mediated posttranslational regulation of PPARd. Quantitative
RT-PCR confirmed a significant increase of endogenous miR-
199a, miR-214, and Dnm3os transcript abundance in cardio-344 Cell Metabolism 18, 341–354, September 3, 2013 ª2013 Elseviemyocytes upon exposure to hypoxia (2% O2) (Figure 2F),
indicating hypoxia as a primary stimulus for the expression of
mature miR-199a and miR-214 via transcriptional regulation of
DNM3os. Locked nucleotide acid (LNA) knockdown probes for
miR-199a and/or miR-214 exhibited a strong and specific
repression of the target miRs as quantified by PCR (Figures
S1B and S1C). LNA-based knockdown of miR-199a and miR-
214 inhibited the hypoxia-mediated PPARd downregulation (Fig-
ure 2G). Interestingly, knockdown of miR-214 abrogated the
hypoxia-induced downregulation of PPARd more effectively
than when miR-199a was targeted (Figure 2G). These results
indicate a more pronounced role for miR-214 than miR-199a in
hypoxia-mediated knockdown of PPARd. Ventricular deletion
of Hif1a in mice was previously used to implicate a Hif1a-PPARg
axis in hypertrophy-induced PPARg activation, metabolic re-
programming, and contractile dysfunction (Krishnan et al.,
2009). Accordingly, we tested whether cardiac-specific Hif1a
deletion would also abrogate PPARd expression under baseline
conditions or after pressure overload. Western blotting demon-
strated that PPARd expression was reduced after pressure
overload, and this reduction was efficiently prevented by
cardiac-specific Hif1a deletion (Figures 2H and 2I). In conclu-
sion, the data demonstrate that hypoxia serves as an upstream
stimulus for Dnm3os andmiR-199a214 expression in the heart
in a hypoxia- and/or Hif1a-dependent manner.
Conditional Targeted Deletion of PPARd Causes Severe
Cardiac Dysfunction
To investigate whether maintenance of PPARd expression is
required for normal myocardial homeostasis and to bypass the
early embryonic lethality of PPARd null mice (Barak et al.,
2002), we provoked deletion of a floxed PPARd (PPARdF/F) allele
using a tamoxifen-inducible Cre recombinase under the control
of the cardiac-specific a-myosin heavy-chain promoter
(aMHC). Specificity of PPARd gene deletion was shown by
real-time RT-PCR for all three endogenous PPAR isoforms,
demonstrating that our genetic intervention did not affect PPARa
or PPARg transcripts, but resulted in a strong and selective
downregulation of PPARd transcripts (Figure S2A). We forced
PPARd gene deletion at the age of 8 weeks and noted that within
5 days after tamoxifen delivery, aMHC-MCM-PPARdF/F mice
displayed signs of inactivity and a weak condition compared to
all control groups. Indeed, up to 25% of tamoxifen-treated
aMHC-MCM-PPARdF/F mice died within 1 week after initiation
of the treatment, and this mortality rate increased to 75% during
the following 2 weeks (data not shown). Upon autopsy, tamox-
ifen-treated aMHC-MCM-PPARdF/F displayed severely enlarged
hearts (Figure S2B).
Cardiac tissue from these mice revealed intricate features of
clinical heart failure, including hypertrophiedmyofibers, myocyte
disarray, and interstitial fibrosis in hearts (Figure S2B), which was
reflected by doubling of heart weight at the whole-organ level
(Figure S2C). These data demonstrate that conditional cardiac-
specific deletion of PPARd in the adult heart causes rapid
cardiac remodeling, which results in multiple clinical signs of
end-stage heart failure and reduced survivability. Cardiac geom-
etry and function was assessed noninvasively by echocardiogra-
phy at 2 weeks after tamoxifen treatment (Figure S2D; Table S1).
At this time point, tamoxifen-treated aMHC-MCM-PPARdF/Fr Inc.
Figure 2. Hypoxia Regulates Expression of the miR-199a214 Cluster
(A) Schematic representation of luciferase reporter constructs harboring intact or mutated proximal DNM3os promoter region.
(B) Activity assay of luciferase reporter construct, driven by the DNM3os promoter after induction of Hif1a or Twist1 expression, in HEK 293 cells.
(C) Western blot analysis of endogenous PPARd and GAPDH in WT and Dnm3os knockout (KO) mice.
(D) Quantification of GAPDH-corrected protein levels of PPARd from (C).
(E) Activity assay of a PPARd 30 UTR luciferase reporter construct in HEK 293 cells exposed to hypoxic conditions (2% O2) for the annotated periods.
(F) Real-time PCR analysis of transcript abundance for miR-199a, miR-214, and DNM3os.
(G)Western blot analysis of endogenous PPARd andGAPDH in neonatal rat cardiomyocytes transfected with scrambled LNA control (scr), LNA against miR-199a
(LNA 199a), LNA against miR-214 (LNA 214), or both LNA againstmiR-199a and LNA against miR-214 (LNA 199a/214) and exposed to a hypoxic environment (2%
O2) for 3 days.
(H) Western blot analysis of endogenous PPARd and GAPDH in WT and Hif1a KO mice.
(I) Quantification of GAPDH-corrected protein levels of PPARd from (H). *p < 0.05 versus corresponding control group; #p < 0.05 versus corresponding
experimental group (error bars are SEM). See also Figure S1.
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tility, as evidenced by a 50% decrease in fractional shortening
(Figure S2E), and severe left ventricular dilation (Figure S2F).
These data indicate that conditional cardiac-specific deletion
of PPARd provoked progressive functional and geometrical
deterioration consistent with a heart failure phenotype, including
potent reactivation of stress-induced embryonic genes such as
Acta1,Nppb,Myh7, andNppa (Figure S2G). Moreover, we noted
a substantial decrease in transcript abundance for Cd36 and
hadha, without changes in Slc2a1 transcript abundance (Fig-
ure S2H), indicating a reduction in fatty acid transport capacity
and oxidation. Conclusively, deletion of PPARd in the adult heart
induces rapid and spontaneous cardiac dysfunction, inductionCell Meof fetal hypertrophic marker genes, and selective downregula-
tion of genes involved in fatty acid metabolism.
miR-214 Silencing Improves Cardiac Contractility
and Derepresses PPARd
Antagomirs are RNA-like oligonucleotides that are reverse
compliment to mature microRNAs and harbor various modifica-
tions for ribonuclease (RNase) protection and pharmacologic
properties such as enhanced tissue and cellular uptake. Antago-
mirs efficiently silence microRNAs in most tissues in vivo (Kru¨tz-
feldt et al., 2005). To intervene in the targeted downregulation of
PPARd bymiR-199a214 in cardiac disease conditions, we sub-
jected mice to transverse aortic constriction pressure overloadtabolism 18, 341–354, September 3, 2013 ª2013 Elsevier Inc. 345
Figure 3. Silencing miR-214 or miR-199a Differentially Improves Cardiac Dysfunction
(A) Design of antagomir treatment study.
(B) Quantitative RT-PCR analysis of miR-199a, miR-214, miR-199b, miR-107, miR-133a, miR-25, and miR-181a expression in mice hearts after vehicle or
antagomir-199a treatment.
(C) Quantitative RT-PCR analysis of miR-199a, miR-214, miR-199b, miR-107, miR-133a, miR-25, and miR-181a expression in mice hearts after vehicle or
antagomir-214 treatment.
(legend continued on next page)
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Table 1. Morphometric and Echocardiographic Characteristics of Wild-Type Mice Treated with Vehicle, Antagomir-199a, or
Antagomir-214 and Subjected to Sham or Transverse Aortic Constriction Surgery
Sham TAC
Vehicle Antagomir-199a Antagomir-214 Vehicle Antagomir-199a Antagomir-214
n 8 7 8 8 8 9
BW (g) 29 ± 1 27 ± 1 26 ± 1 26 ± 1 29 ± 1 28 ± 1
LV mass (mg) 98 ± 4 102 ± 8 102 ± 8 130 ± 6* 155 ± 12*# 139 ± 10*
LV mass/BW (mg/g) 3.50 ± 0.18 3.80 ± 0.30 3.96 ± 0.58 4.95 ± 0.20* 5.49 ± 0.48* 5.07 ± 0.33*
IVSd (mm) 0.86 ± 0.04 0.90 ± 0.04 0.89 ± 0.06 0.99 ± 0.07* 1.07 ± 0.05* 0.99 ± 0.04*
IVSs (mm) 1.31 ± 0.11 1.30 ± 0.08 1.25 ± 0.06 1.32 ± 0.08 1.46 ± 0.08* 1.35 ± 0.06
LVIDd (mm) 3.86 ± 0.11 3.69 ± 0.13 3.81 ± 0.08 4.19 ± 0.05* 4.07 ± 0.14* 4.24 ± 0.13*
LVIDs (mm) 2.36 ± 0.08 2.41 ± 0.15 2.62 ± 0.11 3.30 ± 0.08* 3.07 ± 0.17* 3.01 ± 0.15*
LVPWd (mm) 0.91 ± 0.07 1.00 ± 0.09 0.93 ± 0.09 0.94 ± 0.07 1.17 ± 0.11* 1.00 ± 0.06
LVPWs (mm) 1.33 ± 0.06 1.37 ± 0.09 1.34 ± 0.09 1.18 ± 0.08 1.41 ± 0.10# 1.30 ± 0.05#
EF (%) 77 ± 1 75 ± 3 72 ± 2 51 ± 5* 56 ± 4* 64 ± 2*#
FS (%) 39 ± 4 38 ± 3 35 ± 2 21 ± 1* 25 ± 3* 29 ± 1*#
E/A (mm/s) 1.45 ± 0.08 1.57 ± 0.12 1.58 ± 0.13 2.04 ± 0.13* 1.58 ± 0.14# 1.72 ± 0.13#
Data are expressed as means ± SEM. TAC, transverse aortic constriction; sham, sham-operated control group; BW, body weight; LV, left ventricular;
IVSd, interventricular septal thickness at end diastole; IVSs, interventricular septal thickness at end systole; LVIDd, left ventricular internal dimension at
end diastole; LVIDs, left ventricular internal dimension at end systole; LVPWd, left ventricular posterior wall thickness at end diastole; LVPWs, left ven-
tricular posterior wall thickness at end systole; EF, ejection fraction; FS, fractional shortening; E/A, Doppler E/A ratio.*p < 0.05 versus sham group
treated with control antagomir; #p < 0.05 versus experimental group.
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199a ormiR-214 for 3 consecutive days at 3-week intervals (Fig-
ure 3A). To verify silencing efficiency of antagomir-199a and
antagomir-214, quantitative RT-PCR was performed (Figures
3B and 3C). The specificity of the antagomirs used was verified
by measuring the expression of other microRNAs (Figures 3B
and 3C). Sham-operated mice treated with vehicle, antagomir-
199a, antagomir-214 showed no signs of histopathology or alter-
ations in heart size (Figures S3A–S3C). Vehicle-treated mice
showed substantial cardiac enlargement, displayed hypertrophi-
ed myofibers, myocyte disarray, and interstitial fibrosis upon he-
modynamic stress (Figure 3D), and displayed significantly
increased heart weights (Figure 3E). No significant reduction in
heart weight was observed in antagomir-199a- or antagomir-
214-treated mice that underwent TAC surgery (Figures 3D and
3E). Antagomir-199a- or antagomir-214-treated pressure-over-
loaded hearts displayed less hypertrophied myofibers, myocyte
disarray, and reduced fibrosis, with the effects more pronounced
for mice treated with antagomir-214 (Figure 3D). Analysis of car-
diac function by M-mode echocardiography at 6 weeks demon-
strated an increase in left ventricular internal diameter (LVID) in(D) Representative images of H&E (top panels), Sirius red-stained (middle pane
6 weeks of sham or TAC surgery, treated with vehicle or antagomirs.
(E) Gravimetric analysis of corrected heart weights of mice after 6 weeks of sham
(F) Representative M-mode images in mice hearts after 6 weeks of sham or TAC
(G–J) Quantification by echocardiography of LV internal diameter at systole (LVID
ventricular filling velocity (E/A) (J) of mice hearts after 6 weeks of sham or TAC s
(K) Western blot analysis of endogenous PPARd and GAPDH levels in mice hearts
antagomir-214.
(L) Quantification of GAPDH-corrected protein levels of PPARd.
(M and N) Real-time PCR analysis of transcript abundance for glucose metabolism
after 6 weeks of sham or TAC surgery, treated with vehicle or antagomirs. *p
experimental group (error bars are SEM). See also Figure S3.
Cell Memice subjected to pressure overload and treated with vehicle,
which was slightly reduced upon antagomir-214 treatment (Fig-
ures 3F and 3G). Importantly, the decrease in systolic and dia-
stolic contractility observed in vehicle-treated mice subjected
to TAC surgery was significantly improved by either antagomir-
199a or antagomir-214 treatment (Figures 3H–3J; Table 1).
Furthermore, antagomir-214 treatment was able to fully dere-
press PPARd levels following hemodynamic stress (Figures 3K
and 3L). To analyze the effect of antagomir-214 treatment on
metabolism, we performed RT-PCRs for both fatty acid and
glucose marker genes. Cardiac pressure overload did not alter
the expression of genes implicated in glucose metabolism (Fig-
ure 3M). In contrast, pressure overload induced a pronounced
reduction in key genes involved in fatty acid metabolism,
including acyl-coenzyme A dehydrogenase, medium-chain
(Acadm), CD36 antigen (Cd36), and diacylglycerol O-acyltrans-
ferase 2 (Dgat2), which were fully restored upon antagomir-214
treatment (Figure 3N). Antagomir-214 treatment did not influ-
ence the reactivation of stress-induced fetal genes, including
Nppa, Nppb, Acta1, and Myh7 (Figure S3D). Taken together,
these data demonstrate that single miR-199a or miR-214ls), or WGA-labeled (lower panels) histological sections of mice hearts after
or TAC surgery, treated with vehicle or antagomirs.
surgery, treated with vehicle or antagomirs.
s) (G), ejection fraction (EF) (H), fractional shortening (%FS) (I), and early-to-late
urgery, treated with vehicle or antagomirs.
after 6 weeks of sham or TAC surgery, treated with vehicle, antagomir-199a, or
marker genes (M) and fatty acid metabolism marker genes (N) in mice hearts
< 0.05 versus corresponding control group; #p < 0.05 versus corresponding
tabolism 18, 341–354, September 3, 2013 ª2013 Elsevier Inc. 347
Figure 4. Antagomir-Mediated Silencing of Both mir-199a and miR-214 Attenuates Cardiac Remodeling
(A) Design of antagomir treatment study.
(B) Pressure gradients across the transverse aorta measured noninvasively to validate the TAC procedure.
(C) Representative images of H&E (top panels), Sirius red-stained (middle panels), or WGA-labeled (lower panels) histological sections of mice hearts after
6 weeks of sham or TAC surgery, treated with vehicle or antagomirs.
(D) Gravimetric analysis of corrected heart weights of mice after 6 weeks of sham or TAC surgery, treated with vehicle or antagomirs.
(E) Representative M-mode images in mice hearts after 6 weeks of sham or TAC surgery, treated with vehicle or antagomirs.
(F and G) Quantification by echocardiography of LV internal diameter at systole (LVIDs) (F) and fractional shortening (%FS) (G) of mice hearts after 6 weeks of
sham or TAC surgery, treated with vehicle or antagomirs.
(H) Western blot analysis of endogenous PPARd and GAPDH levels in mice hearts after 6 weeks of sham or TAC surgery, treated with vehicle or antagomirs.
(legend continued on next page)
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Table 2. Echocardiographic Analysis of Mice Following Sham Operation or Transverse Aortic Constriction with or without Double
Antagomir-199a and Antagomir-214 Treatment
Sham TAC
Vehicle Antagomir-199a214 Vehicle Antagomir-199a214
n 7 6 7 6
IVSd (mm) 0.98 ± 0.10 0.83 ± 0.14 1.29 ± 0.07* 1.23 ± 0.14*
IVSs (mm) 1.79 ± 0.05 1.68 ± 0.07 1.74 ± 0.06 1.98 ± 0.09*#
LVIDs (mm) 2.55 ± 0.22 2.10 ± 0.13 3.75 ± 0.17* 2.52 ± 0.26#
LVIDd (mm) 4.35 ± 0.12 4.12 ± 0.22 4.78 ± 0.14* 4.38 ± 0.18#
LVPWs (mm) 1.80 ± 0.08 2.09 ± 0.08 1.49 ± 0.10 1.97 ± 0.16*
LVPWd (mm) 0.91 ± 0.07 1.27 ± 0.14 1.11 ± 0.07* 1.23 ± 0.08
FS (%) 47 ± 1 45 ± 1 25 ± 1* 38 ± 1*#
Data are expressed as means ± SEM. LV, left ventricular; IVSd, interventricular septal thickness at end diastole; IVSs, interventricular septal thickness
at end systole; LVIDd, left ventricular internal dimension at end diastole; LVIDs, left ventricular internal dimension at end systole; LVPWd, left ventricular
posterior wall thickness at end diastole; LVPWs, left ventricular posterior wall thickness at end systole; FS, fractional shortening.*p < 0.05 versus sham
group treated with vehicle; #p < 0.05 versus experimental group.
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ing and differentially restored cardiac contractility, PPARd
expression, and key genes involved in fatty energy metabolism.
miR-199a214 Silencing Attenuates Cardiac
Remodeling and Dysfunction
Next, we intervened in miR-199a214 induction in cardiac dis-
ease conditions by subjecting mice to transverse aortic constric-
tion pressure overload for 6 weeks and treating them with anta-
gomirs for bothmiR-199a andmiR-214 for 3 consecutive days at
3-week intervals (Figure 4A). To ensure equal pressure gradients
among the experimental groups, noninvasive pressure gradients
across the transverse aorta were measured (Figure 4B). Vehicle-
treated mice showed substantial cardiac enlargement upon
biomechanical stress (Figure 4C), whereas antagomir-
199a214-treated mice displayed significantly reduced heart
weights (Figure 4D). Sham-operated mice treated with vehicle
or antagomir-199a214 showed no signs of histopathology (Fig-
ure 4C). In contrast, cardiac tissue of vehicle-treated mice sub-
jected to pressure overload displayed hypertrophied myofibers,
myocyte disarray, and interstitial fibrosis, while mice treated with
antagomir-199a214 displayed normal myocyte arrangement
and significantly reduced hypertrophy and fibrosis (Figure 4C;
Figure S4A). Analysis of cardiac function by M-mode echocardi-
ography at 6 weeks showed an increase in LVID and a propor-
tional decrease in systolic contractility (FS) in mice subjected
to pressure overload and treated with vehicle (Figures 4E–4G;
Table 2). Importantly, treatment with antagomir-199a214 dere-
pressed PPARd levels even in sham-operated animals and
restored PPARd expression following hemodynamic stress (Fig-
ures 4H and 4I), but did not influence PPARa expression (Fig-
ure S4B), further underscoring a specific role for PPARd. To
analyze the effect of antagomir treatment onmetabolism in these
hearts, we performed RT-PCRs for both fatty acid and glucose
marker genes. Neither cardiac pressure overload nor antago-(I) Quantification of GAPDH-corrected protein levels of PPARd.
(J) Real-time PCR analysis of transcript abundance for glucose metabolism mar
6 weeks of sham or TAC surgery, treated with vehicle or antagomirs. *p < 0.05 vers
group (error bars are SEM). See also Figure S4.
Cell Memir-199a214 treatment altered the expression of genes impli-
cated in glucose metabolism, including those encoding solute
carrier family 2 facilitated glucose transporter member 1 and
member 4 (Slc2a1, Slc2a4) and hexokinase 1 (Hk1), in mouse
hearts exposed to pressure overload (Figure 4J). In contrast, car-
diac pressure overload induced pronounced changes in key
genes involved in fatty acid metabolism, including acyl-coen-
zyme A dehydrogenase, long chain (Acadl) and Acadm, indi-
cating restoration of fatty acid metabolism (Figure 4K).
miR-199a214 Silencing Restores Mitochondrial Fatty
Acid Metabolism
Mitochondria play a crucial role in maintaining the energy ho-
meostasis in the heart muscle (Marin-Garcia et al., 2001). Since
in vivo antagomir-based silencing of miR-199a and miR-214 re-
sulted in a restoration of PPARd expression and genes involved
in fatty acid metabolism, we investigated whether mitochondrial
ultrastructure was influenced. Transmission electron micro-
scopy (TEM) assessment of heart sections showed salient mito-
chondrial disarray in pressure-overloaded mouse hearts
(Figure 5A). Treatment with antagomir-199a214 normalized
mitochondrial alignment in mice and restored I band width (Fig-
ure 5A), with unaltered expression of mitochondrial complex I–V
components in pressure overload-induced cardiac dysfunction
(Figure 5B; Figure S5A). We next assessed mitochondrial respi-
ration in isolated cardiac mitochondria, fueled by two types of
substrates: the carbohydrate-derived substrate pyruvate and
the fatty acid-derived substrate palmitoyl-CoA (in the presence
of carnitine) (Hoeks et al., 2010). Briefly, after the addition of sub-
strate, maximal ADP-stimulated (state 3) respiration was deter-
mined. Subsequently, the leak rate (i.e., the respiratory rate in
the presence of the ATP-synthase inhibitor oligomycin [state
4]) and the maximal respiratory capacity (i.e., the respiratory
rate after addition of the chemical uncoupler FCCP [state U])
were assessed. These respiratory analyses revealed clearker genes (J) and fatty acid metabolism marker genes (K) in mice hearts after
us corresponding control group; #p < 0.05 versus corresponding experimental
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Figure 5. miR-199a214 Silencing Preserves Mitochondrial Ultrastructure and Restores Fatty Acid Oxidation
(A) Transmission electron microscopy of heart sections from mice after 6 weeks of sham or TAC surgery, treated with vehicle or antagomirs.
(B) Western blot analysis using a cocktail of monoclonal antibodies, directed against various proteins of the electron transport chain (ETC) complexes of
mitochondria from mice hearts after 6 weeks of sham or TAC surgery, treated with vehicle or antagomirs.
(C and D) Oxygen flux in mitochondria isolated from mouse cardiac tissue after 6 weeks of sham or TAC surgery, treated with vehicle or antagomirs. ADP-driven
(state 3) and uncoupled (state U) oxygen flow was measured in the presence of pyruvate (C) and palmitoyl-CoA + carnitine (D) in mitochondria.
(E) Differentially expressed proteins detected by cardiac proteomics and computational analysis of the potential miR-214 seed regions presence and/or the
conserved number of PPRE sites present in the 10 kb promoter region. Depicted in orange are mitochondrial located genes.
(F) Model depicting the activation of hypoxia-mediated expression of themiR-199a214 cluster under cardiac stress via the Hif1a/Twist1 pathway, leading to the
targeting and subsequent downregulation of PPARd. This results in perturbed mitochondrial fitness and reduced fatty acid metabolism. Antagomir-mediated
silencing ofmiR-199a andmiR-214 derepresses PPARd expression and normalizes cardiac energy homeostasis. *p < 0.05 versus corresponding control group;
#p < 0.05 versus corresponding experimental group (error bars are SEM). See also Figure S5 and Table S2.
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pacity of the heart upon pressure overload and treatment with
antagomir-199a214 (Figures 5C and 5D). Thus, when isolated
cardiac mitochondria were fueled with the carbohydrate-derived
substrate pyruvate, ADP-stimulated, oligomycin-insensitive as
well as FCCP-induced respiration was similar across all groups
(Figure 5C). On the other hand, pressure overload considerably350 Cell Metabolism 18, 341–354, September 3, 2013 ª2013 Elseviereduced mitochondrial fatty acid oxidative capacity, as evi-
denced by a significant reduction in both the ADP-stimulated
(25%) and the maximally uncoupled respiration (20%) upon
the fatty acid substrate palmitoyl-CoA (Figure 5D). The leak
rate (state 4 respiration) remained unaffected by pressure over-
load. Interestingly, the reduced fatty acid oxidative capacity
upon pressure overload was completely restored byr Inc.
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indicating that both ADP-stimulated and the maximally un-
coupled respiration rate upon palmitoyl-Coa + carnitine was
similar to the respective respiration rates observed in control an-
imals. Single microRNAs likely simultaneously influence expres-
sion of up to 100 target genes (Hu et al., 2012). Given the strong
restoration of mitochondrial fatty acid oxidative capacity and
cardiac contractility of the hemodynamically challenged heart
achieved by antagomir-199a214, we interrogated (using an un-
biased proteomics screen) whether additional proteins were
influenced either directly by silencing miR-199a214 or indi-
rectly by reactivation of PPARd (Table S2). Accordingly, we de-
tected an additional 20 differentially expressed proteins (five of
which were mitochondrial) in pressure-overloaded hearts upon
miR-199a214 silencing, many of which harbored potential
miR-199a (Figure S5B) or miR-214 seed regions and/or con-
tained PPAR response elements (PPREs) in their promoter
region (Figure 5E), suggesting thatmiR-199a214 silencing pro-
vokes specific alterations on the cardiac mitochondrial prote-
ome in addition to PPARd derepression. Altogether, our data
suggest amechanismwherebymyocardial hypoxia, a character-
istic of heart failure, induces expression of members of the
miRNA cluster miR-199a214 that actively downregulate
several mitochondrial and cardiac targets including PPARd,
provoking a switch toward a glycolytic metabolic profile that
contributes to heart failure (Figure 5F).
DISCUSSION
Although the regulation of metabolism is modulated by a variety
of factors, the molecular mechanisms that drive the metabolic
shift in the failing heart are still incompletely understood. The he-
modynamically challenged myocardium exhibits a return to the
fetal metabolic pattern that is hallmarked by impaired mitochon-
drial fatty acid oxidation and a shift to further reliance on glucose
metabolism (Rajabi et al., 2007; Razeghi et al., 2001). Here, we
propose a mechanism that integrates two characteristics of
heart failure, hypoxia and a metabolic shift toward glycolysis,
involving a microRNA cluster and a variety of target genes
including PPARd. We demonstrate that under hemodynamic
stress, regional hypoxia in the heart activates DNM3os, a non-
coding RNA transcript that harbors the miRNA cluster miR-
199a214, in a HIF-dependent and/or HIF-independent manner.
As one mechanistic explanation, the miRNA-mediated repres-
sion of PPARd activity participates in a specific defect in mito-
chondrial respiration using fatty acids as substrate, resulting in
a metabolic shift of the heart from predominant reliance on fatty
acid utilization in the healthy myocardium toward increased reli-
ance on glucose metabolism in the failing heart.
Recently, Gan and colleagues demonstrated thatmuscle-spe-
cific overexpression of PPARd increased glucose oxidation in
mitochondria through the reprogramming of glucose utilization
pathways via interaction with the exercise-inducible AMP-acti-
vated protein kinase (AMPK) and myocyte enhancer factor 2A
(MEF2A) (Gan et al., 2011). This effect may be selective for skel-
etal muscle, given that in our study we did not observe enhanced
glucose utilization after reactivation of PPARd in the hemody-
namically stressed heart, but further lend evidence toward a
role for PPARd in the regulation of mitochondrial fueling.Cell MeTargeted expression of an activated form of PPARd in skeletal
muscle induced a muscle fiber type switch, hereby conferring
resistance to obesity and improved metabolic profiles, in part
through increased mitochondrial function (Wang et al., 2004).
Furthermore, conditional transgenic mice expressing a constitu-
tively active form of PPARd in cardiomyocytes displayed
enhanced mitochondrial capacity at baseline and under condi-
tions of pressure overload (Liu et al., 2011). In contrast, Wang
et al. (2010) demonstrated that inducible gene targeting of
PPARd in the adult heart resulted in decreased mitochondrial
function, concomitant with a hypertrophic response and
decreased cardiac function. These data confirm our findings
that restoring PPARd levels in the heart maintains oxidative ca-
pacity of mitochondria and protects against heart failure.
Conversely, our proteomics analysis of the miR-199a214-
silenced myocardium has given us a first unbiased indication
of additional factors further involved in the phenotypic changes
we observed. As expected, a large number of them are mito-
chondria specific (Coq9, Dlat, Uqcrfs1, Ndufv2, Hspe1, and
Nnt); however, their precise regulation by this pathway remains
to be experimentally validated. As a first attempt to elucidate
their potential dependency on amiR-199a214/PPARd circuitry,
we identified a number of potential PPREs as well as a number of
potential binding sites formiR-199a and/ormiR-214. These data
suggest possible first or second degree interactions with our
proposed mechanism and open up future studies to elucidate
their function in cardiac energy metabolism.
As a key determinant of progression to heart failure, hypoxia is
postulated to be a driving force for adverse cardiac remodeling.
Pressure overload and ischemia often occur together clinically,
as in patients with hypertension and coronary disease. As miR-
214 was recently demonstrated to act as a regulator of cardio-
myocyte Ca2+ homeostasis and survival during acute cardiac
ischemia-reperfusion injury (Aurora et al., 2012), the possible
use of future miR-214 therapeutics may be of more benefit in
chronic cardiac (hypertrophic) remodeling processes rather
than acute cardiac ischemic conditions. Indeed, pathologically
hypertrophied hearts show significant decreased capillary den-
sity and associated hypoxia (Friehs et al., 2004). In a mouse
model with cardiomyocyte-restricted deletion of the von Hip-
pel-Lindau protein (VHL), a component of the E3 ubiquitin ligase
that inhibits Hif1a, chronic activation of the Hif1a hypoxia
response pathway is observed (Lei et al., 2008), resulting in pro-
gressive cardiac degeneration with lipid accumulation and
decreased mitochondrial number leading to severe heart failure.
Next to its role in modulating the fate of mesenchymal cell pop-
ulation during development, Twist1 has been also implicated in a
wide range of neoplasias, including gastric, liver, and breast can-
cers (Karreth and Tuveson, 2004; Mironchik et al., 2005; Niu
et al., 2007). Analysis of Twist1 expression showed a ubiquitous
expression in various mouse tissues with diverse expression
patterns, with relatively high expression in the cardiac ventricle
(Lu et al., 2011), which is in line with the proposed regulatory
role for Dnm3os expression. Dnm3os-deficient mice display de-
fects in skeletal formation and body growth during embryonic
development (Watanabe et al., 2008).
Taken together, our data show that miR-199a and miR-214
play a pivotal role in PPARd-mediated regulation of cardiacmito-
chondrial substrate fluxes with impact on cardiac structure andtabolism 18, 341–354, September 3, 2013 ª2013 Elsevier Inc. 351
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inant reliance on fatty acid utilization in the healthy myocardium
toward increased reliance on glucose metabolism in the failing
heart. Our observations indicate that human heart failure arises
from derangements in gene regulatory circuits, where molecular
understanding of these circuits will aid in predicting sites of ther-
apeutic intervention.
EXPERIMENTAL PROCEDURES
Human Heart Samples
Tissue was taken from the left ventricular free wall of patients with end-stage
heart failure secondary to ischemic heart disease or from patients undergoing
heart transplantation because of terminal heart failure. Control tissue was
taken from the left ventricular free wall of refused donor hearts.
Mouse Models
Mouse models included Dnm3oslacZ mice (Watanabe et al., 2008), Hif1aF/F
mice (Ryan et al., 1998) interbred with myosin light chain 2v (MLC2v)-Cre
mice (Chen et al., 1998) (Krishnan et al., 2009), and PPARdF/F mice (Jackson
Laboratories) interbred with mice harboring a tamoxifen-regulated form of
Cre recombinase (MerCreMer) under control of the murine Myh6 promoter
(Sohal et al., 2001). All protocols were performed according to institutional
guidelines and approved by local Animal Care and Use Committees.
Aortic Banding and Transthoracic Echocardiography
Transverse aortic constriction or sham surgery was performed in 2- to 3-
month-old BL6CBAF1 mice by subjecting the aorta to a defined 27G constric-
tion between the first and second truncus of the aortic arch as described
previously (Bourajjaj et al., 2008; Rockman et al., 1991). Noninvasive, Doppler
echocardiographic analysis was performed as described previously in detail
(da Costa Martins et al., 2010).
Antagomir Administration
Antagomirs, 20–23 nt long RNA oligos complementary to miR-199a or miR-
214, were purchased from Fidelity Systems or Integrated DNA Technologies
and synthesized essentially as previously described (Kru¨tzfeldt et al., 2005),
except that cholesterol was linked through a hydroxyprolinol linkage. All anta-
gomirs were 20-Ome modified, contained a 30 cholesterol-TEG (15 atom
triethylene glycol), 2 phosphorothioate (PT) bonds at the very first 50 end,
and PT bonds between the last 30 bases. All antagomirs were HPLC purified
and desalted before use.
Northern Blot Analysis
Northern blot analysis was performed as described previously (da Costa Mar-
tins et al., 2010) using 30-digoxigenin-labeled locked nucleic acid oligonucleo-
tides for hsa-miR-199a, hsa-miR-214, mmu-miR-199a, mmu-miR-214, or U6
small nuclear RNA (Rnu6-2) and detected with an antibody to 30-digoxigenin
(Roche).
MicroRNA and mRNA Real-Time PCR
Primer sequences are described in Table S3. Real-time PCR was performed
using miScript SYBR Green PCR Kit (QIAGEN) on a Bio-Rad iCycler.
Primary Cardiomyocytes, Transient Transfections, and Luciferase
Reporter Assays
Cardiomyocyte cultures were isolated by enzymatic dissociation of 1- to 2-
day-old neonatal rat hearts, as described previously (De Windt et al., 2000),
and transfected with miR-199a, miR-214, or scrambled-miR precursor mole-
cules (Ambion) using oligofectamine (Invitrogen). Human embryonic kidney
(HEK) 293 cells were transfected with pMIR reporter plasmids harboring the
30 UTR of human PPARd using FuGENE 6 (Roche) reagent, followed by trans-
fection withmiR-199a,miR-214, or scrambled miR precursor molecules using
oligofectamine. For cotransfection assays, pGL3-Dnm3os promoter con-
structs were cotransfected with constructs expressing a stabilized form of
Hif1a and/or Twist1. pRL-TK, containing the thymidine kinase promoter driving
Renilla luciferase, was included to correct for transfection efficiency.352 Cell Metabolism 18, 341–354, September 3, 2013 ª2013 ElsevieWestern Blot Analysis
Immunoprecipitation, SDS PAGE electrophoresis, and blotting were per-
formed as described previously (De Windt et al., 2000). Primary antibodies
that were used for western blotting include polyclonal anti-PPAR-delta
(Abcam), anti-PPAR-alpha (Abcam), monoclonal anti-GAPDH (Chemicon),
and monoclonal total OXPHOS cocktail (MitoSciences), followed by corre-
sponding horseradish peroxidase (HRP)-conjugated secondary antibodies
and enhanced chemiluminescence (ECL) detection.
Histological Analysis and Immunofluorescence Microscopy
Hearts were arrested in diastole, paraffin embedded, sectioned at 4 mm, and
stained with fluorescein isothiocyanate (FITC)-labeled wheat germ agglutinin
(WGA), hematoxylin and eosin (H&E), Sirius red, or biotinylated Griffonia sim-
plicifolia lectin I (GS-I) to visualize cardiac vascularization.
Isolation of Cardiac Mitochondria and Mitochondrial Respirometry
Cardiac tissuewas processed for mitochondrial isolation bymechanical Potter
homogenization, repeated centrifugation, and gentle resuspension. Mitochon-
drial respiratory rates were analyzed using an oxygraph (OROBOROS Instru-
ments) (Hoeks et al., 2010).
Proteomics Analysis
Cardiac tissue was diced, PBS washed with proteinase inhibitors (Sigma-
Aldrich), and incubated with 0.1% SDS, and the SDS solution was stored
frozen. Next, samples were incubated with 4 M guanidine hydrochloride with
proteinase inhibitors, proteins were precipitated by centrifugation, and the pel-
lets were kept at20C. The gel bands were subjected to in-gel digestion with
trypsin, and tryptic peptides were separated on a Nanoflow LC System (Dio-
nexUltiMate 3000), elutedwith a 40min gradient, and the column (Dionex Pep-
Map C18) was coupled to a nanospray source (PicoView). Spectra were
collected from an ion trap mass analyzer (LTQ Orbitrap XL). Tandem mass
spectrometry (MS/MS) was performed on the top six ions in each MS scan us-
ing the data-dependent acquisitionmodewith dynamic exclusion enabled.MS
spectra were separately analyzed in MaxQuant Software. To construct a MS/
MS peak list file, up to the top eight peaks per 100 Da window were extracted
and submitted to search against a concatenated forward and reverse version
of theUniProtKB/Swiss-Prot mouse database. A principal component analysis
was performed using the normalized high/low ratios of all proteins from all
samples. Significant differences were identified using the Bioconductor limma
package and Bayesian statistics to moderate variance across proteins and
calculate a p value.
Statistical Analysis
The results are presented as mean ± SEM. All statistical analyses were per-
formed with Prism software (GraphPad), consisting of an ANOVA test followed
by Tukey’s post hoc test when group differences were detected at the 5% sig-
nificance level or Student’s t test when comparing two experimental groups.
Differences were considered significant when p < 0.05.
SUPPLEMENTAL INFORMATION
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